First Patient Dosed in Gene Therapy Trial for LOPD

First Patient Dosed in Gene Therapy Trial for LOPD

285176

First Patient Dosed in Gene Therapy Trial for LOPD

Spark Therapeutics has dosed the first patient in the Phase 1/2 RESOLUTE clinical trial of SPK-3006, an experimental gene therapy for people with late-onset Pompe disease (LOPD). “Dosing the first participant in the Phase 1/2 RESOLUTE trial of investigational SPK-3006 for late-onset Pompe disease is an important milestone and first step to what we hope will ultimately allow us to bring an innovative gene therapy to these patients,” Gallia G. Levy, MD, PhD, Spark’s chief medical…

You must be logged in to read/download the full post.